Srámek V, Novák I, Matĕjovic M, Rokyta R, Nalos M, Hora P, Pittrová H
Medical Department I, Charles University Hospital Plzen, Czech Republic,
Intensive Care Med. 1998 Mar;24(3):262-4. doi: 10.1007/s001340050562.
A 72-year-old patient with multiple myeloma was admitted to the intensive care unit because of hypercalcemic crisis and acute renal failure. After 7 days of comprehensive therapy including diuretics steroids, calcitonin, and intermittent hemodialysis (IHD) with low-calcium dialysate, calcium still reached high levels between IHD treatments and thrombocytopenia developed after chemotherapy. CVVHDF with calcium-free bicarbonate dialysate was started. Anticoagulation with 2.2% citrate was performed in order to chelate calcium, and thus treat the hypercalcemia, and to provide regional anticoagulation, and thus reduce the risk of bleeding due to thrombocytopenia. CVVHDF with citrate anticoagulation was continued for 6 days, and standard heparin anticoagulation was started when the hypercalcemia and thrombocytopenia abated.
一名72岁的多发性骨髓瘤患者因高钙血症危象和急性肾衰竭入住重症监护病房。在接受包括利尿剂、类固醇、降钙素以及使用低钙透析液进行间歇性血液透析(IHD)在内的7天综合治疗后,透析间期血钙仍维持在高水平,且化疗后出现了血小板减少。遂开始采用无钙碳酸氢盐透析液进行连续性静脉-静脉血液透析滤过(CVVHDF)治疗。使用2.2%枸橼酸盐进行抗凝,以螯合钙从而治疗高钙血症,并提供局部抗凝作用,进而降低因血小板减少导致出血的风险。采用枸橼酸盐抗凝的CVVHDF持续了6天,当高钙血症和血小板减少缓解后,开始使用标准肝素抗凝。